StreetAlpha.app
Home › Stocks › SION

Sionna Therapeutics, Inc. (SION)

Healthcare
$3.07
▼ −1.60%
LAST CLOSE · NOV 17

Sionna Therapeutics develops experimental medicines for cystic fibrosis, a genetic disease that affects the lungs and other organs. It last closed at $3.07 on Nov 17, down 1.60% on the day.

AI Auto Pilots
Is SION in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$109.5M
EPS (diluted)
−$2.43
Free cash flow
−$79.6M
Valuation
Market cap
$138.9M
45.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$83.9M
At Sep 30
Shareholder equity
$240.5M
Shares outstanding
45.2M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$61.7M−$61.7MFY2024FY2025: −$75.3M−$75.3MFY2025

From SION's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated SION in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 95.4% upside

Based on 1 analyst who set a price target on SION in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $3.07.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $3.07
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
WedbushTarget raised
Sep 15Hold$5 → $6
WedbushDowngrade
Aug 11Hold$53 → $5
GuggenheimMaintained
Aug 7Buy$60
Freedom BrokerDowngrade
May 20Hold$38
StifelMaintained
May 18Buy$55
DateFirmActionRatingPrice target
Sep 15WedbushTarget raisedHold$5 → $6
Aug 11WedbushDowngradeHold$53 → $5
Aug 7GuggenheimMaintainedBuy$60
May 20Freedom BrokerDowngradeHold$38
May 18StifelMaintainedBuy$55
Loading…

Technical Analysis

SION · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 18% below its 20 day and 55% below its 50 day average. It is 806% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $3.00, and the nearest resistance the Pivot R1 at $3.15.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 11.3%/day
Key levels
$54.9752 week high+1690.6%
$27.82200 day average+806.2%
$16.92100 day average+451.1%
$4.7550 day average+54.7%
$3.85Swing high (Nov 11)+25.4%
$3.6220 day average+17.9%
$3.15Pivot R1+2.6%
$3.07Pivot+0.0%
$3.07Last close
$3.0052 week low−2.3%
$3.00Pivot S1−2.3%
Indicators
RSI (14)28.78Oversold below 30Oversold
MACD-0.55Above its signal lineBullish
Stochastic7.1Near the bottom of its rangeOversold
ADX (14)38.9Trending down
Williams %R-93.6Oversold below −80, overbought above −20Oversold
CCI (20)-174.7Oversold below −100, overbought above 100Oversold
Rate of change−15.9%Change over 10 sessionsBearish
ATR (14)$0.35Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SION

What happened before

See how SION did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in SION in the last 90 days.

Loading…

See today’s whale options flow across the market →

SION Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲95 buying vs 79 selling
  • ▼Held by funds -6.0 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding136147−7.5%
In funds' top 1026−66.7%
Held by funds100.8%106.7%−6.0 pts
New / increased45 / 5034 / 57+4.4%
Reduced / sold out25 / 5440 / 8+64.6%
Put/call ratio0.976.74−85.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SION institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SION is in one of them and how their past SION trades turned out.

SION in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SION in an article yet. Here's the latest on the wider market.

About Sionna Therapeutics

Sionna Therapeutics is a drug developer based in Waltham, Massachusetts. It is developing medicines for people with cystic fibrosis, an inherited disease that causes thick mucus to build up in the lungs, pancreas and other organs. Its candidates are designed to stabilize a part of the CFTR protein called NBD1, which is affected by the most common cystic fibrosis mutation. The company is still testing these candidates in clinical trials.

Headquarters
Waltham, MA